Paul Goss
Overview
Explore the profile of Paul Goss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Goss P, Allan A, Rodenhiser D, Foster P, Chambers A
APMIS
. 2008 Oct;
116(7-8):552-68.
PMID: 18834402
Tumor dormancy is a significant clinical problem. Primary treatment of a cancer may be apparently successful, and yet the tumor may recur either locally or as distant metastases years or...
12.
Pater J, Goss P, Meyer R
J Clin Oncol
. 2008 May;
26(16):2787-8.
PMID: 18509191
No abstract available.
13.
Ma X, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, et al.
Clin Cancer Res
. 2008 May;
14(9):2601-8.
PMID: 18451222
Purpose: Histologic tumor grade is a well-established prognostic factor for breast cancer, and tumor grade-associated genes are the common denominator of many prognostic gene signatures. The objectives of this study...
14.
Gligorov J, Pritchard K, Goss P
Breast
. 2007 Dec;
16 Suppl 3:S1-9.
PMID: 18061455
In patients with early-stage breast cancer, all recurrences are associated with an increased risk of mortality, especially distant metastases. Adjuvant tamoxifen therapy for 5 years is effective in postmenopausal patients...
15.
Goss P, Bondarenko I, Manikhas G, Pendergrass K, Miller Jr W, Langecker P, et al.
J Clin Oncol
. 2007 Nov;
25(31):4961-6.
PMID: 17971594
Purpose: To compare time to progression (TTP) with a steroidal aromatase inhibitor (AI) atamestane (ATA) combined with toremifene (TOR; complete estrogen blockade) versus letrozole (LET) in receptor-positive advanced breast cancer...
16.
Goss P, Wu M
Breast
. 2007 Aug;
16 Suppl 2:S114-9.
PMID: 17719783
Aromatase (estrogen synthetase) inhibitors (AIs) have been incorporated into adjuvant treatment of early-stage breast cancer in post-menopausal women and their role in pre-menopausal is being investigated. Several questions regarding AIs...
17.
Moy B, Kirkpatrick P, Kar S, Goss P
Nat Rev Drug Discov
. 2007 Jul;
6(6):431-2.
PMID: 17633789
No abstract available.
18.
Goss P, von Eichel L
J Steroid Biochem Mol Biol
. 2007 Jul;
106(1-5):40-8.
PMID: 17627816
Antagonizing estrogen by inhibition of aromatase has become a mainstay of adjuvant endocrine therapy in women with hormone receptor positive (ER+) breast cancer. Recent trials have shown an incremental gain...
19.
Pater J, Goss P, Ingle J, Shelley W, Shepherd L
J Clin Oncol
. 2005 Apr;
23(12):2862-3.
PMID: 15838002
No abstract available.
20.
Arun B, Goss P
Semin Oncol
. 2004 Jun;
31(2 Suppl 7):22-9.
PMID: 15179621
Several studies have suggested that cyclooxygenase-2 (COX-2) expression is associated with parameters of aggressive breast cancer, including large tumor size, positive axillary lymph node metastases, and HER2-positive tumor status. Studies...